Quintrio
Home

Stock overview

Adagene Inc. American Depositary Shares

ADAG

Adagene Inc is a platform-driven, clinical-stage biotechnology company focused on the discovery and development of novel antibody-based cancer immunotherapies. The Company leverages computational biology to design and develop novel antibodies. Powered by its Dynamic Precision Library (DPL) platform, which fuels its NEObody, SAFEbody, and POWERbody technologies, it is developing a pipeline of immunotherapies. Its candidate, ADG126 (muzastotug), an anti-CTLA-4 SAFEbody, is in phase 1b/2 and phase 2 clinical development for metastatic microsatellite-stable colorectal cancer. Its clinical-stage products include ADG126 and ADG116, investigational fully human anti-CTLA-4 mAbs generated through SAFEbody and NEObody technologies.

Last trade $1.56
Day change -$0.04 (-2.50%)
Day range $1.45 – $1.67
Volume 1,421,560
Market cap $107M

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

No ratio data was found for ADAG.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

No quarterly income statement data was found for ADAG.

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
GlobeNewswire Inc.

Adagene and City of Hope Open Clinical Trial to Test New Therapy for Patients with Hard-to-Treat Colorectal Cancer

Adagene Inc. and City of Hope announced the launch of a Phase 1 clinical trial to evaluate a combination therapy of ivonescimab and muzastotug (ADG126) for patients with advanced microsatellite stable colorectal cancer. The trial will enroll up to 36 patients and aims to determine optimal dosing before potentially combining the immunotherapy with chemotherapy drugs 5-FU and irinotecan. The study is investigator-initiated and designed to accelerate treatment options for patients whose disease has resisted standard treatments.

GlobeNewswire Inc.

Adagene to Participate in the Guggenheim Securities 3rd Annual Healthcare Innovation Conference

Adagene Inc. (Nasdaq: ADAG), a clinical-stage biotechnology company, announced that senior management will participate in a fireside chat and one-on-one meetings at the Guggenheim Securities 3rd Annual Healthcare Innovation Conference on November 9-11, 2026 in Boston. The company is advancing its lead clinical program muzastotug (ADG126), a masked anti-CTLA-4 SAFEbody currently in Phase 1b/2 and Phase 2 studies for microsatellite stable metastatic colorectal cancer in combination with anti-PD-1 therapy.

GlobeNewswire Inc.

Adagene Reports Full Year 2025 Financial Results and Provides Corporate Update

Adagene reported 29% overall response rate for muzastotug (ADG126) in MSS colorectal cancer patients at the 20 mg/kg dose, with median overall survival of 19.4 months at 10 mg/kg dose. The company demonstrated improved tolerability with 4% discontinuation rate and no Grade 4-5 adverse events across 67 patients. With $74.5 million in cash as of December 31, 2025, Adagene expects runway into early 2028 and plans to initiate a registration trial once optimal dose is established.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily

No stock split records found.